TNFRSF14

Human

E.coli(Fc)

Recombinant Human HVEM-Fc/TNFRSF14

HVEM belongs to the TNF Receptor superfamily of transmembrane proteins, and plays a role in the activation of T-cells and other lymphocytes. It is expressed in various cells and tissues, including spleen, thymus, lung, macrophages, and T-cells. HVEM activation induces a signaling cascade that results in the induction of transcription factors NF-κB and AP-1. LIGHT (TNFSF14) and TNF-β (TNFSF1) function as the ligands for HVEM, which can also bind specifically to herpes simplex virus glycoprotein D. Soluble HVEM, which tends to form disulfide-linked heterodimeric complexes in solution, can act as a “receptor decoy” resulting in inhibition of the activity of the HVEM ligands, LIGHT and TNF-β. Recombinant Human HVEM-Fc Chimera is a 376 amino acid fusion protein that contains an N-terminal domain corresponding to the extracellular region of HVEM, and a C-terminal domain corresponding to residues 102 to 330 of human IgG1.

Approximately 58 kDa

LPSCKEDEYP VGSECCPKCS PGYRVKEACG ELTGTVCEPC PPGTYIAHLN GLSKCLQCQM CDPAMGLRAS RNCSRTENAV CGCSPGHFCI VQDGDHCAAC RAYATSSPGQ RVQKGGTESQ DTLCQNCPPG TFSPNGTLEE CQHQTKCSWL VTKAGAGTSS SHWVEPKSSD KTHTCPPCPA PEFEGAPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPTP IEKTISKAKG QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK

Sterile Filtered White lyophilized (freeze-dried) powder.

> 95 % by SDS-PAGE and HPLC analyses.

Fully biologically active when compared to standard. The biologically active as determined by its ability to inhibit TNF-beta -mediated cytotoxicity using murine L929 cells.

< 0.1 EU per 1μg of the protein by the LAL method.

Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH7.4, with 3 % Trehalose.

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

100, 500μg